| dc.contributor.author | Tyndall, M | |
| dc.contributor.author | Agoki, E | |
| dc.contributor.author | Ombette, J | |
| dc.contributor.author | Slaney, LA | |
| dc.contributor.author | D'Costa, LJ | |
| dc.contributor.author | Plummer, FA | |
| dc.contributor.author | Plourde, PJ | |
| dc.contributor.author | Ndinya-Achola, JO | |
| dc.date.accessioned | 2013-04-26T08:37:06Z | |
| dc.date.available | 2013-04-26T08:37:06Z | |
| dc.date.issued | 1992 | |
| dc.identifier.citation | J Infect Dis. 1992 Oct;166(4):919-22 | en |
| dc.identifier.uri | http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/1527431 | |
| dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/16972 | |
| dc.description.abstract | Sexually transmitted diseases (STDs) have a significant adverse effect on reproductive and child health worldwide. The control of STDs such as gonorrhea is therefore an absolute priority. Cefixime, an oral third-generation cephalosporin with in vitro activity similar to that of ceftriaxone, may be an effective candidate for the treatment of gonorrhea. The efficacy of a single oral 400-mg dose of cefixime was compared with that of a single intramuscular 250-mg dose of ceftriaxone for the treatment of Neisseria gonorrhoeae urethritis in 190 men and cervicitis in 46 women in Nairobi, Kenya. A bacteriologic cure was recorded in 100% of 63 evaluatable patients treated with ceftriaxone and 118 (98%) of 121 evaluatable patients treated with cefixime. Cefixime, as a single oral dose, is an effective alternative for the treatment of uncomplicated gonococcal urethritis in men and cervicitis in women | en |
| dc.language.iso | en | en |
| dc.title | Single-dose cefixime versus single-dose ceftriaxone in the treatment of antimicrobial-resistant Neisseria gonorrhoeae infection. | en |
| dc.type | Article | en |
| local.publisher | Department of Medical Microbiology, University of Nairobi, Kenya. | en |
